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A B S T R A C T   
Discovery of the adipose tissue as a major source of signaling molecules almost three decades ago set a novel 
physiological paradigm that paved the way for the identification of metabolic organs as endocrine organs. Ad-
ipocytes, the main adipose tissue cell type, do not only represent the principal site of energy storage in form of 
triglycerides, but also produce a variety of molecules for short and long distance intercellular communication, 
named adipokines, which coordinate systemic responses. Although the best known adipokines identified and 
characterized hitherto are leptin and adiponectin, novel adipokines are continuously being described, what have 
significantly helped to elucidate the role of adipocyte biology in obesity and associated comorbidities. One of 
these novel adipokines is high-mobility group box 1 (HMGB1), a ubiquitous nuclear protein that has been 
recently reported to be dysregulated in obese dysfunctional adipocytes. Although the classical function of 
HMGB1 is related to inflammation and immunity, acting as an alarmin, novel advances evidence an active 
implication of HMGB1 in tissue remodeling and fibrosis. This review summarizes the current evidence on the 
mechanisms controlling HMGB1 release, as well as its role as a regulator of adipocyte function and extracellular 
matrix remodeling, with special emphasis on the potential of this novel adipokine as a target in the obesity 
treatment.   
1. Introduction 
Adipose tissue is an active and dynamic organ that plays an essential 
role in the regulation of whole-body homeostasis. The discovery of 
leptin (Zhang et al., 1994) opened a novel field of study on adipocyte 
biology as a source of secreted molecules. These molecules are known as 
adipokines and mediate short and long distance intercellular connec-
tions (acting as signal mediators) that are essential for maintaining 
systemic homeostasis, and in some cases, acting as potential biomarkers 
of different diseases (Gupta and Attie, 2019; Funcke and Scherer, 2019; 
Huang and Xu, 2021). The nature of these signal mediators released by 
the adipose tissue is widely heterogeneous, including proteins, lipids, 
and metabolites (Funcke and Scherer, 2019; Huang and Xu, 2021). Most 
adipokines are secreted via classical endoplasmic reticulum (ER) 
secretory pathway; however, some signal mediators are secreted via 
non-classical ER/Golgi-independent secretion pathways. One of these 
unconventionally secreted adipokines is high-mobility group box 1 
(HMGB1) (Kwak et al., 2020). 
HMGB1 was identified in 1973 as a member of the high-mobility 
group (HMG) protein family (Goodwin et al., 1973). Classical func-
tions related to HMGB1 are modulation of cellular stress responses, by 
playing critical roles as a DNA chaperone, promotion of sustained 
autophagy, and protection from apoptotic cell death by acting intra-
cellularly or extracellularly as a damage-associated molecular pattern 
molecule (DAMP) (Kang et al., 2015). In fact, this ubiquitously 
expressed protein acts as an alarmin (i.e., endogenous molecule signal-
ling tissue/cell damage) mediating the adaptative immune response in 
different tissues via extracellular secretion (Bianchi et al., 2017; 
Ezquerro et al., 2020; Lin et al., 2020; Wang et al., 2021). Once it has 
been secreted, HMGB1 exerts different actions through binding to its 
receptors. To date, no specific receptor has been described for HMGB1. 
The most receptors described for HMGB1 are CXC chemokine receptors 
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(CXCR4), Receptor for Advanced Glycation End products (RAGE), 
toll-like receptor 2 (TLR2) and toll-like receptor 4 (TLR4) (Kwak et al., 
2020). 
HMGB1, which is physiologically localized in nuclear compartments, 
lacks a secretory signal peptide but can undergo several extensive post- 
transcriptional modifications (PTMs), including acetylation, phosphor-
ylation, glycosylation and oxidation, that increase its cytoplasmic 
accumulation and modulate its extracellular secretion (Kwak et al., 
2020). Importantly, these PTMs also modulate the activity of HMGB1. 
Thus, it has been described that HMGB1 contains reversibly acetylated 
Lys residues that are critical for active HMGB1 secretion by cells while, 
in contrast, non-acetylated HMGB1 is released passively by cells (Bian-
chi et al., 2017). These evidences were firstly described in immune cells 
(monocytes and macrophages) (Bonaldi et al., 2003; Lu et al., 2014; 
Yang et al., 2014). Specifically, Bonaldi described 17 acetylated lysines, 
that can be acetylated independently and showing a high complexity of 
possible hyperacetylation of HMGB1 in human monocytes (Bonaldi 
et al., 2003). Recently, evidences of HMGB1 acetylation in other cell 
lines (endothelial cells HUVEC, HBMVEC) are described in response to 
damage or infections (Rabadi et al., 2015; Lee et al., 2020). However, 
further analysis are necessary to define the possible role of hyper-
acetylation of HMGB1 and also the possible acetylated lysine in other 
cell lines or tissues, focusing special attention in adipocytes (Fig. 1). 
An important role of HMGB1 oxidation on the functions attributed to 
this protein has been also demonstrated. Indeed, depending on its redox 
status, HMGB1 can trigger different effects, wherein the reduced form or 
all-thiol-HMGB1 (frHMGB1) promotes chemoattractive effects, and 
disulfide-HMGB1 (dsHMGB1) form exerts pro-inflammatory effects (see 
review by (Kwak et al., 2020)). In contrast, fully oxidized-HMGB1 has no 
effects (Kwak et al., 2020). Analysis of HMGB1 redox state of in different 
tissues in response to acute damage demonstrated tissue-specific effects 
of this alarmin depending on redox modulation (Ferrara et al., 2020). 
Specifically, this study showed an increase in dsHMGB1 expression in 
normal spleen and liver, while the expression in muscle was very low 
(Ferrara et al., 2020). Additional data provided by Tirone showed that 
reduced form of HMGB1 induce tissue muscle and liver regeneration via 
CXCR4, in contrast, no effects were observed using dsHMGB1. Specif-
ically, fully reduced HMGB1 (frHMGB1) increase the satellite cell 
marker Pax7, the myogenic factors MyoD and Myogenin, promoting 
muscle regeneration (Tirone et al., 2018). Moreover, the treatment with 
3S, which is resistant to oxidation and act similar to fr-HMGB1, induced 
a significant increase of these progenitors’ markers expression earlier 
and faster that control suggesting the dual function depending on 
alternative redox forms of HMGb1could mediate sequential physiolog-
ical processes after tissue injury (Tirone et al., 2018). 
Although it wide clear the role of HMGB1 on cell progenitors, not 
only in muscle. In fact, similar effects were observed in other tissue like 
hepatocytes and expansion of hepatic progenitor cells (HPCs), which 
could be related to hepatocarcinoma aggressiveness (Khambu et al., 
2018; Hernandez et al., 2018). However, no evidence of HMGB1 redox 
state is revised in these studies. In contrast, Ved et al., showed a 
reduction of oligodendrocyte progenitor cells in presence of 
disulfide-HMGB1 (dsHMGB1) (Ved et al., 2021). These data corroborate 
the dual effect of this alarmin depending on redox modulation and 
opening a new possibility to understand complexity of this molecule. 
Due to the relevance of progenitor cells in the context of adipose tissue 
biology (Sebo et al., 2018), especially in the context of obesity, 
analyzing the possible relationship between HMGB1 redox and Pax7 in 
adipocytes could be of great relevance and probably could be considered 
as a possible therapeutic target. However, no data related to PTM or 
redox state in adipose tissue has been described yet. 
2. HMGB1, adipose tissue, obesity and insulin resistance 
Previous data reported by our group showed that the expression of 
HMGB1 depends on the adipose tissue status. In mice with lipodys-
trophy, which have subcutaneous adipose tissue with insufficient ca-
pacity to store fat, HMGB1 protein expression was increased in visceral 
adipose tissue from the lipodistrophic mice compared to control mice 
(Peinado et al., 2011). Studies in humans showed decreased HMGB1 
expression levels in omental and subcutaneous fat from obese subjects as 
compared to lean individuals, being the reduction of protein expression 
more evident in obese and insulin resistant subjects in SC fat. In contrast, 
no differences were observed in omental fat (Guzmán-Ruiz et al., 2014). 
These data evidenced the importance of adipose tissue functional status 
in the control of HMGB1 expression in both subcutaneous and omen-
tal/visceral fat. However, further studies are necessary to elucidate 
depot specific HMGB1 protein expression in adipose tissue. 
Moreover, intracellular localization of HMGB1 in adipose tissue cells 
seems also to depend on the cellular status. Thus, nuclear HMGB1 is 
translocated into the cytosol and passively released by necrotic adipo-
cytes from obese mice and humans (Zhang et al., 2017). In addition, it is 
also actively released by adipocytes exposed to external stimulus 
inducing immune responses (Zhang et al., 2017). Specifically, bacterial 
lipopolysaccharide (LPS) activates HMGB1 by primary adipocytes from 
lean and obese patients (Guzmán-Ruiz et al., 2014; Gunasekaran et al., 
2013). The proinflammatory mediator TNFα also increases the active 
release of HMGB1 in 3T3-L1 adipocytes (Shimizu et al., 2016). Notably, 
as for LPS, insulin has been also shown to increase HMGB1 
nucleus-to-cytosol transfer and secretion by primary adipocytes from 
lean and obese patients (Guzmán-Ruiz et al., 2014). Given that all these 
external stimuli are present in the pathology of obesity and insulin 
resistance, it seems likely that HMGB1 may be actively released by ad-
ipocytes in obese individuals, and thus contribute to the chronic 
low-grade inflammatory state that characterizes the obese adipose tissue 
(Guzmán-Ruiz et al., 2014). 
Extracellular HMGB1 released by adipocytes can display both local 
and long-distance actions. As an autocrine mediator, extracellular 
HMGB1 has proinflammatory effects on primary human adipocytes, 
increasing the secretion of the pro-inflammatory cytokines, Interleukin- 
6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), via toll-like 
receptor 4 (TLR-4) activation (Gunasekaran et al., 2016). Other 
studies have shown that exposure of the preadipocyte cell line SW872 to 
HMGB1 increases in IL-6 release through activation of the multiligand 
RAGE, independent of TLR (Nativel et al., 2013). In this line, a recent 
longitudinal study in young adults has shown that circulating HMGB1 is 
positively associated with hs-CRP, IL-6, and TNF-α (Chen et al., 2020). 
Positive correlations of HMGB1 levels with plasma IL-6 have been also 
reported by other authors (Wang et al., 2015). The differences observed 
Fig. 1. Release of HMGB1 from adipocytes under pathophysiological 
conditions. HMGB1 can be passively released after cell death. Nuclear HMGB1 
is translocated into the cytosol in necrotic cells to induce autophagy and che-
moattraction, promoting dead cell degradation. HMGB1 is also considered a 
danger-associated molecular pattern (DAMP) molecule and a danger signal 
(infection, trauma, pathogen …) that can also be actively transported from the 
nucleus to the cytosol and the extracellular to promote inflammatory responses. 
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in HMGB1 signalling on adipocytes (TRL vs. RAGE) could be accounted 
for by PTMs of HMGB1 and/or the oxidative status of this protein yet 
whether these modifications occur in the adipose tissue in response to 
obesity or obesity-associated pathologies remain to be investigated 
(Kwak et al., 2020). 
Moreover, HMGB1 endocrine effects on other tissues may contribute 
to maintain the inflammatory status in adipose tissue. Thus, exposure of 
pancreatic INS-1 beta cells to HMGB1 increases insulin release 
(Guzmán-Ruiz et al., 2014). Also, we observed that the exposition of 
human adipocytes to insulin, increase HMGB1 translocation into cytosol 
(Guzmán-Ruiz et al., 2014). As it has been observed in other models (Lu 
et al., 2014), the translocation of HMGB1 into cytosol are related to 
HMGB1 release, so, based on these previous data, probably this effect 
could promote chronic HMGB1 release by adipocytes and generating a 
vicious cycle and a prolonged activation of the immune response 
(Fig. 2). However, additional studies are necessaries to confirm this 
hypothesis. Interestingly, elevated plasma HMGB1 levels were detected 
in subjects with obesity and type 2 diabetes (T2D) (Guzmán-Ruiz et al., 
2014; Wang et al., 2015), as well as in association with higher levels of 
obesity measures (Chen et al., 2020). A recent study has revealed plasma 
HMGB1 as an independent risk factor for T2D development and pro-
gression (Huang et al., 2019), while other has shown the association of 
HMGB1 with subclinical cardiovascular risk among young adults (Chen 
et al., 2020). Nevertheless, exists a relationship between HMGB1 plasma 
levels, insulin secretion and T2D. However, additional studies are 
necessary to elucidate the role of HMGB1 and molecular mechanism 
involved in the pathogeny of insulin resistance. 
In sum, by acting either locally or on distant target cells, HMGB1 
could promote a chronic inflammatory state in the adipose tissue, which 
represents a hallmark of obesity-induced metabolic complications. In 
this scenario, HMGB1 could represent a novel therapeutic target in 
obesity-associated pathologies. Several studies have reported an 
improvement in the pro-inflammatory response associated with a 
reduction of extracellular HMGB1 expression. Thus, Mazur-Bialy 
showed that irisin inhibited the production and release of HMGB1 by 
both adipocyte and macrophage cell lines, diminishing the development 
of obesity-related metabolic inflammation (Mazur-Bialy, 2019). Inter-
estingly, previous results in human preadipocytes demonstrated that, in 
contrast to insulin, no extracellular release of HMGB1 was observed 
upon ghrelin exposure (Guzmán-Ruiz et al., 2014), yet ghrelin reduces 
HMGB1 expression and improves TNFα–induced cell death in hepato-
cytes (Ezquerro et al., 2020). Adiponectin also reduced HMGB1 release 
and improved inflammation and insulin resistance in patients with 
obesity (Shimizu et al., 2016). This data further supports a role for 
actively released HMGB1 as a pro-inflammatory adipokine, which may 
contribute to the progression of metabolic syndrome and, therefore, 
highlighting HMGB1 as a key target in obesity-associated pathologies. 
Thus, analyze the role of novel processes related to insulin resistance in 
obesity such as meta-inflammation or fibrosis could suggest novel 
possible targets to improve insulin resistance, opening new focus of 
study that may be key to understand the complexity of the molecule 
HMGB1 in the development of insulin resistance and T2D. 
3. HMGB1, meta-inflammation and adipose tissue remodeling 
Metabolic inflammation or “meta-inflammation” plays an essential 
role in the development of obesity-associated metabolic complications 
(McNelis and Olefsky, 2014). This effect is mediated, in part by mac-
rophages located within the adipose tissue. In obesity, the macrophage 
population could be 10-fold higher that in lean conditions and adopt 
variable states of activation (Weisberg et al., 2003). Alterations in 
macrophage polarization contributes to obesity-induced insulin resis-
tance (Li et al., 2018). Thus, resident macrophages of lean subjects 
exhibit a M2 or anti-inflammatory phenotype, while in obesity there is a 
change into M1 or pro-inflammatory macrophages, promoting inflam-
mation and attracting more M1-macrophages to infiltrate the adipose 
tissue (Crewe et al., 2017; Lee et al., 2018; Pessentheiner et al., 2020). 
As HMGB1 could act as a pro-inflammatory adipocytokine, the 
relationship between HMGB1 and macrophage pro-inflammatory acti-
vation should be also considered. Although some studies have demon-
strated a relationship between HMGB1 and macrophage activation, the 
underlying mechanisms are still not fully understood (Wagner, 2014). It 
has been described that macrophages exposed to HMGB1 secrete 
pro-inflammatory cytokines, inducing an inflammatory response 
(Andersson et al., 2000; Wagner, 2014). Recent studies by Ghosh et al. 
demonstrated a direct role of HMGB1 on mediating macrophage polar-
ization in adipose tissue (Ghosh et al., 2016). To be more specific, Ghosh 
et al. demonstrated that HMGB1 promoted macrophage polarization 
into M1 phenotype by increasing Type I Interferon induction via circu-
lating plasmacytoid dendritic cells (pDC) recruitment into the adipose 
tissue. As previously mentioned, HMGB1 promotes IL-6 and MCP-1 
secretion from adipocytes (Gunasekaran et al., 2016; Nativel et al., 
2013), which could also contribute to macrophage polarization into M1 
phenotype. In all, available evidence supports that HMGB1, by acting 
locally, could increase M1 macrophage population in the adipose tissue, 
thus activating an additional pathway that may contribute to the 
development of obesity inflammation and associated insulin resistance 
(Fig. 3). Moreover, HMGB1 could contribute to macrophage polarization 
by promoting chemoattraction of novel macrophage in response to 
damage (Bianchi et al., 2017) (Fig. 3). 
4. HMGB1 and fibrosis 
It has been proposed that there are three dominant contributors to 
adipose tissue dysfunction in obesity: unresolved inflammation, fibrosis, 
and insufficient angiogenesis (Crewe et al., 2017). Disentangling the 
complex relationship between these three hallmarks of obesity could be 
key to understand the pathogenesis of obesity. With regard to fibrosis in 
the obese adipose tissue, it is well known that it contributes to the 
development of insulin resistance and diabetes (Lackey et al., 2014; 
Muir et al., 2016). As HMGB1 has been demonstrated to exert an active 
participation in insulin resistance in obesity, a role of this protein in 
fibrosis development could be questioned. In fact, recent studies have 
demonstrated the possible relevance of HMGB1 in the development of 
fibrosis in several tissues. 
In the heart, HMGB1 contributes to cardiac allograft vasculopathy/ 
fibrosis by promoting the activation of transforming growth factor beta 
1 (TGF-β1)/Smad signaling (Zou et al., 2021). Thus, recombinant 
HMGB1 promoted the release of active TGF-β1 from cardiac fibroblasts 
and macrophages in vitro. Moreover, treatment with a 
HMGB1-neutralizing antibody attenuated cardiac fibrosis by decreasing 
Fig. 2. An overview of HMGB1 in adipocyte biology and insulin resis-
tance. HMGB1 is passively released by necrotic adipocytes and actively 
released by adipocytes exposed to inflammatory signals and/or obesogenic 
stimulus (i.e insulin, LPS or TNFα). Extracellular HMGB1 has autocrine effects 
on adipocytes, increasing the inflammatory response, and endocrine effects on 
other cell types, such as pancreatic beta cells, increasing insulin release. All 
these effects result in increased HMGB1 plasma levels, suggesting the potential 
utility of this alarmin as a biomarker of insulin resistance. 
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fibroblasts-to-myofibroblasts conversion and reducing synthesis and 
release of TGF-β1 (Zou et al., 2021). Similar results were observed in 
liver fibrosis, wherein HMGB1 increased both hepatic stellate cells 
activation and expression of collagen type I alpha 1 chain (COL1A1) and 
actin alpha 2 (ACTA2) protein levels (Ge et al., 2020). Also, in 
non-alcoholic fatty liver disease (NAFLD) conditions, both human and 
mouse liver tissue samples showed significant up-regulation of HMGB1 
accompanied by an increase in the expression of profibrogenic markers, 
including ACTA2, TGF-β1, COL1A1, and the inhibitor of matrix metal-
loproteinases, TIMP Metallopeptidase Inhibitor 1 (TIMP1) (Tang et al., 
2021). In this line, a dried root commonly used in traditional Chinese 
medicine for the treatment of liver diseases, Astragali Radix, reduced the 
expression of HMGB1 and other pro-inflammatory markers (TLR-4, 
Myd88, RAGE, and NF-κB) in a rat model of liver fibrosis (Wen et al., 
2021). HMGB1 also induced myofibroblast differentiation and extra-
cellular matrix deposition by fibroblasts from human inferior turbinate 
mucosa, increasing ACTA2, fibronectin and collagen production (Lee 
et al., 2021). Likewise, HMGB1 is known to stimulate lung fibroblast to 
produce extracellular matrix in lung fibrosis (Wang et al., 2017). 
Notably, treatment with metformin has been demonstrated to reduce the 
profibrotic effects of HMGB1 in fibroblasts and to improve fibrosis (Song 
et al., 2021). All these data suggest the importance of HMGB1 in the 
development of fibrosis, therefore suggesting the possibility to use 
anti-HMGB1 therapies to improve this tissue damage. However, no data 
related to HMGB1 and fibrosis in adipose tissue has been reported as yet. 
Additional studies are necessary to define the possible role of HMGB1 on 
fibrosis. Therefore, future studies focused on HMGB1 and adipose tissue 
fibrosis will be of special interest to complement our knowledge on 
adipose tissue (dys)function in obesity. 
5. Conclusion 
Targeting HMGB1 could constitute a plausible therapeutic strategy 
for the amelioration of inflammation and inflammatory diseases, as 
occurs in the adipose tissue of obese individuals. Antagonists of HMGB1 
active release could interfere in its cytoplasmic exportation and reduce 
its pro-inflammatory effects. Additional strategies aimed at targetting 
different HMGB1 isoforms (PTMs and oxidative status) could also be of 
interest to control the HMGB1 response. Nevertheless, elucidating the 
exact role of HMGB1 is still necessary to complement our knowledge on 
HMGB1 function, specifically in the adipose tissue, in order to design 
alternative therapeutic strategies for obesity- and inflammatory-related 
diseases. 
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Waguri, S., Werner, S., Oury, T.D., Dong, Z., Yin, X.M., 2018. HMGB1 promotes 
ductular reaction and tumorigenesis in autophagy-deficient livers. J. Clin. Invest. 
128, 2419–2435. https://doi.org/10.1172/JCI91814. 
Kwak, M.S., Kim, H.S., Lee, B., Kim, Y.H., Son, M., Shin, J.S., 2020. Immunological 
significance of HMGB1 post-translational modification and redox biology. Front. 
Immunol. 11, 1–16. https://doi.org/10.3389/fimmu.2020.01189. 
Lackey, D.E., Burk, D.H., Ali, M.R., Mostaedi, R., Smith, W.H., Park, J., Scherer, P.E., 
Seay, S.A., McCoin, C.S., Bonaldo, P., Adams, S.H., 2014. Contributions of adipose 
tissue architectural and tensile properties toward defining healthy and unhealthy 
obesity. Am. J. Physiol. Endocrinol. Metab. 306, 233–246. https://doi.org/10.1152/ 
ajpendo.00476.2013. 
Lee, Y.S., Wollam, J., Olefsky, J.M., 2018. An integrated view of immunometabolism. 
Cell 172, 22–40. https://doi.org/10.1016/j.cell.2017.12.025. 
Lee, S.-H., Cho, J.H., Park, J.-H., Cho, J.-S., Lee, H.-M., 2021. High mobility group box 
chromosomal protein-1 induces myofibroblast differentiation and extracellular 
matrix production via RAGE, p38, JNK and AP-1 signaling pathways in nasal 
fibroblasts. Am. J. Rhinol. Allergy 1–7. https://doi.org/10.1177/ 
1945892421998142. 
Lee, Y.S., Choi, J.Y., Mankhong, S., Moon, S., Kim, S., Koh, Y.H., Kim, J.H., Kang, J.H., 
2020. Sirtuin 1-dependent regulation of high mobility box 1 in 
hypoxia–reoxygenated brain microvascular endothelial cells: roles in neuronal 
amyloidogenesis. Cell Death Dis. 11 https://doi.org/10.1038/s41419-020-03293-0. 
Li, C., Xu, M.M., Wang, K., Adler, A.J., Vella, A.T., Zhou, B., 2018. Macrophage 
polarization and meta-inflammation. Transl. Res. 191, 29–44. https://doi.org/ 
10.1016/j.trsl.2017.10.004. 
Lin, M., Long, J., Li, W., Yang, C., Loughran, P., O’Doherty, R., Billiar, T.R., Deng, M., 
Scott, M.J., 2020. Hepatocyte high-mobility group box 1 protects against steatosis 
and cellular stress during high fat diet feeding. Mol. Med. 26 https://doi.org/ 
10.1186/s10020-020-00227-6. 
Lu, B., Antoine, D.J., Kwan, K., Lundbäck, P., Wähämaa, H., Schierbeck, H., 
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